Surgical Science Sweden AB (publ)
SUSRF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.42 | 1.08 | 0.55 | 0.41 |
| FCF Yield | 1.09% | 3.19% | 1.11% | 0.20% |
| EV / EBITDA | 42.97 | 25.59 | 29.93 | 104.17 |
| Quality | ||||
| ROIC | 2.42% | 3.69% | 3.38% | 3.11% |
| Gross Margin | 67.63% | 69.42% | 66.23% | 72.51% |
| Cash Conversion Ratio | 0.95 | 1.26 | 0.80 | 0.69 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.28% | 34.02% | 97.11% | 53.45% |
| Free Cash Flow Growth | -53.80% | 104.51% | 284.28% | 70.02% |
| Safety | ||||
| Net Debt / EBITDA | -5.37 | -2.77 | -1.54 | -2.65 |
| Interest Coverage | 0.00 | 12.57 | 124.55 | 3.87 |
| Efficiency | ||||
| Inventory Turnover | 1.59 | 1.75 | 2.01 | 0.89 |
| Cash Conversion Cycle | 269.38 | 198.72 | 204.21 | 463.93 |